239 related articles for article (PubMed ID: 14752877)
1. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
7. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
9. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
Thongprasert S
J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
[TBL] [Abstract][Full Text] [Related]
14. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
Marina NM; Rodman J; Shema SJ; Bowman LC; Douglass E; Furman W; Santana VM; Hudson M; Wilimas J; Meyer W
J Clin Oncol; 1993 Mar; 11(3):554-60. PubMed ID: 8445431
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
[TBL] [Abstract][Full Text] [Related]
20. Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC).
Cuomo AM; Robustelli della Cuna FS; Baiardi P; Torazzo R; Preti P; Robustelli della Cuna G
J Chemother; 2001 Aug; 13(4):434-9. PubMed ID: 11589488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
